Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter V Vogel

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Diagnostics (Basel, Switzerland)|November 27, 2021
Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast CancerRamsha Iqbal, Lemonitsa H Mammatas, Tuba Aras, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2013
Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapyBas B Koolen, Kenneth E Pengel, Jelle Wesseling, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2026
Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trialMonique C de Jong, Andrew J Hope, José S A Belderbos, et al.
Breast (Edinburgh, Scotland)|February 19, 2013
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancerBas B Koolen, Kenneth E Pengel, Jelle Wesseling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2009
The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancerIris M C van der Ploeg, Omgo E Nieweg, Bin B R Kroon, et al.
European Radiology|October 29, 2024
Added value of body MRI to detect primary abdominal malignancies in the diagnostic work-up of patients with adenocarcinoma of unknown primaryJeroen R J Willemse, Max J Lahaye, Elisabeth P Goedegebuure, et al.
The British Journal of Radiology|September 19, 2025
Optimizing diagnostic pathways through digital multidisciplinary team management of patients with cancer of unknown primary: a retrospective analysisJeroen R J Willemse, Max J Lahaye, Petur Snaebjornsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2007
18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patientsEsther G C Troost, Wouter V Vogel, Matthias A W Merkx, et al.
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Urology|January 29, 2014
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancerLaura S Mertens, M Carmen Mir, Andrew M Scott, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Diagnostics (Basel, Switzerland)|November 27, 2021
Diagnostic Performance of [<sup>18</sup>F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast CancerRamsha Iqbal, Lemonitsa H Mammatas, Tuba Aras, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2013
Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapyBas B Koolen, Kenneth E Pengel, Jelle Wesseling, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 14, 2026
Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trialMonique C de Jong, Andrew J Hope, José S A Belderbos, et al.
Breast (Edinburgh, Scotland)|February 19, 2013
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancerBas B Koolen, Kenneth E Pengel, Jelle Wesseling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2009
The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancerIris M C van der Ploeg, Omgo E Nieweg, Bin B R Kroon, et al.
European Radiology|October 29, 2024
Added value of body MRI to detect primary abdominal malignancies in the diagnostic work-up of patients with adenocarcinoma of unknown primaryJeroen R J Willemse, Max J Lahaye, Elisabeth P Goedegebuure, et al.
The British Journal of Radiology|September 19, 2025
Optimizing diagnostic pathways through digital multidisciplinary team management of patients with cancer of unknown primary: a retrospective analysisJeroen R J Willemse, Max J Lahaye, Petur Snaebjornsson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2007
18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patientsEsther G C Troost, Wouter V Vogel, Matthias A W Merkx, et al.
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Urology|January 29, 2014
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancerLaura S Mertens, M Carmen Mir, Andrew M Scott, et al.
Pageof 13